Related Experiment Videos
Ambrisentan (Myogen).
1Department of Physiology and Cell Biology The Ohio State University, Columbus 43210-1218, USA. billman.1@osu.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|November 15, 2002
Summary
Ambrisentan and LU-302146 are investigational drugs for treating kidney and cardiovascular conditions. By August 2001, ambrisentan was in Phase II trials for heart failure, hypertension, and kidney issues.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are novel therapeutic agents.
- These compounds are under development by Myogen, licensed from Abbott (formerly BASF Pharma).
Purpose of the Study:
- To evaluate the potential therapeutic applications of ambrisentan and LU-302146.
- Focus on treatment of post-ischemic acute renal failure and cardiovascular diseases.
Main Methods:
- Clinical trials, specifically Phase II trials for ambrisentan.
- Evaluation of efficacy and safety in relevant patient populations.
Main Results:
- By August 2001, ambrisentan had advanced to Phase II clinical trials.
- Indications under investigation include chronic heart failure, hypertension, kidney failure, and pulmonary hypertension.
Conclusions:
- Ambrisentan and LU-302146 show promise for treating significant renal and cardiovascular conditions.
- Ongoing clinical development aims to establish their therapeutic value.